Alphathera

AlphaThera is a US based biotechnology company specializing in antibody labeling reagents. The company developed a unique, site-specific bioconjugation method that enhances assay performance over competing labeling methods. The company was founded by Dr Andrew Tsourkas and Dr. James Hui at the University of Pennsylvania in 2016. They developed the technology of LASIC (Light Assisted Site-specific Conjugation), which led to the creation of oYo-Link® antibody labeling reagents. oYo-Link® reagents enable rapid, covalent, site-specific antibody labeling to a wide range of cargos (e.g. biotin, azide, oligos, fluorescent proteins and more) in just 2 steps - mix and illuminate. Conjugation requires less than 30 seconds hands-on time, and is complete in 2 hours. Unlike other labeling technologies available commercially, no antibody purification is required, as oYo-Link is compatible with all common buffers, including those containing BSA, Tris and Azide, so researchers save valuable time and materials. Furthermore, oYo-Link enables conjugation with as little as 1µg of antibody at concentrations as low as 50µg/mL. AlphaThera's also provides Conjugation Services to researchers that would prefer to outsource their antibody conjugation. AlphaThera’s mission is to remove the complexity and inconsistency that has long been associated with antibody conjugations, making labeling simple, fast and site-specific.